Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers.
Kelloff
Gary J
GJ
National Cancer Institute, Division of Cancer Treatment and Diagnosis, Biomedical Imaging Program, Bethesda, Maryland 20892, USA. kelloffg@mail.nih.gov
O'Shaughnessy
Joyce A
JA
Gordon
Gary B
GB
Hawk
Ernest T
ET
Sigman
Caroline C
CC
D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D017322:Clinical Trials, Phase II as Topic; D017277:Drug Approval; D015195:Drug Design; D006801:Humans; D009369:Neoplasms / Q000473:pathology / Q000517:prevention & control*; D009385:Neoplastic Processes; D010641:Phenotype; D011230:Precancerous Conditions / Q000517:prevention & control*; D011237:Predictive Value of Tests; D015203:Reproducibility of Results
D016588:Anticarcinogenic Agents; D014408:Biomarkers, Tumor